Methods for achieving therapeutically effective doses of anti-CD47 agents
US-12258399-B2 · Mar 25, 2025 · US
This page is not indexed by search engines while we improve data quality.
Willingham Stephen patents
Willingham Stephen is listed as an inventor on 29 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Willingham Stephen |
| Total patents | 29 |
| First publication | Jan 14, 2016 |
| Latest publication | Mar 25, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody
US-12258403-B2 · Mar 25, 2025 · US
Treatment of cancer with combinations of immunoregulatory agents
US-2025066473-A1 · Feb 27, 2025 · US
Treatment of cancer with dual targeting of CD47 and EGFR
US-12037402-B2 · Jul 16, 2024 · US
Methods for treating cancer by achieving therapeutically effective doses of anti-cd47 antibody
US-2023303688-A1 · Sep 28, 2023 · US
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
US-11603404-B2 · Mar 14, 2023 · US
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
US-11518806-B2 · Dec 6, 2022 · US
Methods for achieving therapeutically effective doses of anti-cd47 agents
US-2022289845-A1 · Sep 15, 2022 · US
Methods for achieving therapeutically effective doses of anti-cd47 agents
US-2022251199-A1 · Aug 11, 2022 · US
Treatment of cancer with dual targeting of cd47 and egfr
US-2022033506-A1 · Feb 3, 2022 · US
Recent patents
Latest publications not already listed above.
Methods for achieving therapeutically effective doses of anti-cd47 agents
US-2021380689-A1 · Dec 9, 2021 · US
Use of anti-CD47 agents to enhance immunization
US-11154600-B2 · Oct 26, 2021 · US
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
US-11136391-B2 · Oct 5, 2021 · US
Treatment of cancer with dual targeting of CD47 and EGFR
US-11130813-B2 · Sep 28, 2021 · US
Compositions for achieving therapeutically effective doses of anti-CD47 agents
US-11104731-B2 · Aug 31, 2021 · US
Treatment of cancer with combinations of immunoregulatory agents
US-2021230276-A1 · Jul 29, 2021 · US
Methods for achieving therapeutically effective doses of anti-cd47 agents
US-2021079093-A1 · Mar 18, 2021 · US
Treatment of cancer with dual targeting of cd47 and egfr
US-2019322751-A1 · Oct 24, 2019 · US
Methods for achieving therapeutically effective doses of anti-cd47 agents
US-2019218289-A1 · Jul 18, 2019 · US
Treatment of cancer with dual targeting of CD47 and EGFR
US-10344094-B2 · Jul 9, 2019 · US
Methods for achieving therapeutically effective doses of anti-CD47 agents
US-10301387-B2 · May 28, 2019 · US
Use of anti-cd47 agents to enhance immunization
US-2018353582-A1 · Dec 13, 2018 · US
Use of anti-CD47 agents to enhance immunization
US-10064925-B2 · Sep 4, 2018 · US
Treatment of cancer with combinations of immunoregulatory agents
US-2017210803-A1 · Jul 27, 2017 · US
Treatment of cancer with dual targeting of cd47 and egfr
US-2017166645-A1 · Jun 15, 2017 · US
Methods for achieving therapeutically effective doses of anti-cd47 agents
US-2017145096-A1 · May 25, 2017 · US
Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer
US-9623079-B2 · Apr 18, 2017 · US
Use of Anti-CD47 Agents to Enhance Immunization
US-2016144009-A1 · May 26, 2016 · US
Methods for Achieving Therapeutically Effective Doses of anti-CD47 Agents
US-2016008429-A1 · Jan 14, 2016 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Univ Leland Stanford Junior | 29 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 29 |
| C07K16/2803 | 25 |
| C07K2317/76 | 25 |
| A61P43/00 | 20 |
| A61K2039/505 | 19 |